spacer
home > events calendar
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR
   
  {prev}
EVENTS FOR 2017
{next}  
   
 
EVENTS FOR ICT
 
     

Outsourcing in Clinical Trials New England

6-7 September 2017
Boston

Registration is now open for the flagship conference, OCT New England which will return to Boston this September. Following the tremendous success of the 2016 event, the OCT team have been busy putting together the most content driven, high quality agenda to date. The speaker line-up is the best so far, with senior professionals from across the field currently finalizing their interactive presentations and sessions. More>>

 
email events@arena-international.com
web www.arena-international.com/octnewengland
email Boston, New England, US
 
spacer
Industry Events

5th Annual Peptides Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our highly anticipated 5th Annual Peptides Congress, 16thĖ 17th April 2018, London, UK. Over 450 peptides, proteins and antibodies attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

Banner of Clinical_Trial_New_England_events_95 on Samedan

White Papers

Case Study: Cmedís Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>


News and Press Releases

Charles River Laboratories Acquires KWS BioTest

WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 11, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS enhances Charles Riverís discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement